GENETIC TECHNOLOGIES LIMITED — Major Shareholding Notification 2019

Oct 29, 2019

Form 603

Corporations Act 2001 Section 671B

Notice of initial substantial holder

To Company Name/Scheme Genetic Technologies Limited ACN/ARSN 009 212 328 1. Details of substantial holder (1) Name Peter Irwin Rubinstein, Irwin Biotech Nominees P/L and RIP Opportunities Pty Ltd ACN/ARSN (if applicable) The holder became a substantial holder on 28/10 /19

2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person’s votes (5)	Voting power (6)
OrdinaryFullyPaid Shares(OFP)	248,132,009	248,132,009	6.11%

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
Peter Irwin Rubinstein, Irwin Biotech Nominees P/L and RIP Opportunities Pty Ltd	Direct	248,132,009

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
Irwin Biotech Nominees Pty Ltd	Irwin Biotech Nominees P/L A/C>	Irwin Biotech Nominees P/L A/C>	87,049,310 OFP
Irwin Biotech Nominees Pty Ltd	Irwin Biotech Nominees Pty Ltd	Irwin Biotech Nominees Pty Ltd	28,582,700 OFP (26,582,700 of which are represented by 44,305 American DepositaryReceipts)
RIP Opportunities Pty Ltd Super Fund A/C>	RIP Opportunities Pty Ltd Super Fund A/C>	RIP Opportunities Pty Ltd Super Fund A/C>	132,499,999 OFP (7,500,000 of which are represented by 12,500 American Depositary Receipts)

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)	Consideration (9)	Class and number of securities
		Cash	Non-Cash
Irwin Biotech Nominees Pty Ltd	28/10/19	$0.004 per Share		75,849,310 OFP

100956_1

	RIP Opportunities Pty Ltd	28/10/19	$0.004 per Share		124,999,999 OFP

6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Irwin Biotech Nominees Pty Ltd	Peter Irwin Rubinstein, is a director and shareholder of Irwin Biotech Nominees PtyLtd.
Irwin Biotech Nominees Pty Ltd	Peter Irwin Rubinstein, is a director and shareholder of Irwin Biotech Nominees PtyLtd.
RIP Opportunities Pty Ltd	Peter Irwin Rubinstein, is a director and shareholder of RIP Opportunities PtyLtd and a beneficiaryof the PIR Super Fund.

7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Peter Irwin Rubinstein	Suite 5,Level 1,321 Chapel St Prahran VIC 3181
Irwin Biotech Nominees PtyLtd	Suite 5,Level 1,321 Chapel St Prahran VIC 3181
Irwin Biotech Nominees PtyLtd	Suite 5,Level 1,321 Chapel St Prahran VIC 3181
RIP Opportunities PtyLtd	Suite 5,Level 1,321 Chapel St Prahran VIC 3181

Signature

print name sign here	Peter Irwin Rubinstein capacity
	date 30/10/2019

DIRECTIONS

(1) If there are a number of substantial holders with similar or related relevant interests (eg a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.

• (2) See the definition of “associate” in section 9 of the Corporations Act 2001.

(3)

• (4)

See the definition of “relevant interest” in sections 608 and 671B(7) of the Corporations Act 2001.

The voting shares of a company constitute one class unless divided into separate classes.

(5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.

(6) The person’s votes divided by the total votes in the body corporate or scheme multiplied by 100.

• (7) Include details of:

(a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and

(b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of “relevant agreement” in section 9 of the Corporations Act 2001.

(8) If the substantial holder is unable to determine the identity of the person (eg if the relevant interest arises because of an option) write “unknown”.

(9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

100956_1

GUIDE

This guide does not form part of the prescribed form and is included by ASIC to assist you in completing and lodging form 603.

Signature This form must be signed by either a director or a secretary of the substantial holder. Lodging Period Nil Lodging Fee Nil Other forms to be completed Nil

Additional information

• (a) If additional space is required to complete a question, the information may be included on a separate piece of paper annexed to the form.

• (b) This notice must be given to a listed company, or the responsible entity for a listed managed investment scheme. A copy of this notice must also be given to each relevant securities exchange.

• (c) The person must give a copy of this notice:

  • (i) within 2 business days after they become aware of the information; or (ii) by 9.30 am on the next trading day of the relevant securities exchange after they become aware of the information if:

    • (A) a takeover bid is made for voting shares in the company or voting interests in the scheme; and

    • (B) the person becomes aware of the information during the bid period.

• Annexures To make any annexure conform to the regulations, you must

• 1 use A4 size paper of white or light pastel colour with a margin of at least 10mm on all sides 2 show the corporation name and ACN or ARBN 3 number the pages consecutively 4 print or type in BLOCK letters in dark blue or black ink so that the document is clearly legible when photocopied

• 5 identify the annexure with a mark such as A, B, C, etc 6 endorse the annexure with the words: This is annexure (mark) of (number) pages referred to in form (form number and title)

• 7 sign and date the annexure The annexure must be signed by the same person(s) who signed the form.

Information in this guide is intended as a guide only. Please consult your accountant or solicitor for further advice

166499/1